Workflow
icon
Search documents
有色金属周报:对美关税反制,战略金属价值显现,黄金再迎布局良机-2025-04-07
Tebon Securities· 2025-04-07 07:20
有色金属 优于大市(维持) 证券分析师 翟堃 [Table_Main] 证券研究报告 | 行业周报 市场表现 -29% -22% -15% -7% 0% 7% 15% 22% 29% 2024-04 2024-08 2024-12 有色金属 沪深300 资料来源:德邦研究所,聚源数据 相关研究 1. 《 黄 金 : 万 里 长 征 方 起 步 》, 2025.4.1 2.《赤峰黄金:提产降本推动利润提 升》,2025.4.1 3.《藏格矿业(000408.SZ):巨龙铜 业投资收益大幅增长,巨龙二期稳步 推进》,2025.3.31 资格编号:s0120523050002 邮箱:zhaikun@tebon.com.cn 康宇豪 资格编号:S0120524050001 邮箱:kangyh@tebon.com.cn 研究助理 4.《云铝股份:业绩水平提升,电解 铝产量创历史新高》,2025.3.31 5.《有色金属周报:关税已敲定,地 缘 风 云 再 起 , 坚 定 黄 金 主 线 》, 2025.3.30 有色金属 2025 年 04 月 07 日 有色金属周报:对美关税反制, 战略金属价值显现,黄金再迎布 局良 ...
精卫填“海”系列(十一):应对衰退交易风暴
Tebon Securities· 2025-04-07 05:27
[Table_Main] 证券研究报告 | 海外市场动态跟踪 2025 年 04 月 07 日 海外市场动态跟踪 德邦证券 证券分析师 薛威 资格编号:S0120523080002 邮箱:xuewei@tebon.com.cn 谭诗吟 资格编号:S0120523070007 邮箱:tansy@tebon.com.cn 应对衰退交易风暴 ——精卫填"海"系列(十一) 请务必阅读正文之后的信息披露和法律声明 近期特朗普的关税政策加剧衰退交易,表现为美债利率下行、美元指数下行、美股 下跌、前期价格坚挺的有色金属大幅下跌。我们锚定"经济复苏尾声"、"全球报复 性关税"两个变量,将 1929-1932 年大萧条时期作为参考情形,为后续全球市场 可能的演绎方向提供借鉴。 大萧条时期美国经济处于扩张周期尾声,萧条期间美国出台保护性关税,加剧经济 衰退,与当前的情景较为类似,回顾大萧条时期的资产价格表现: 美债利率整体下行,1931 年阶段性走升。大萧条期间,国债作为避险资产更受投 资者青睐,利率整体下行,但到了 1931 年,由于英国等国家已经宣布放弃金本位, 投资者担心美国也会效仿,开始将美元资产兑换成黄金,为了应对黄金 ...
流动性与机构行为跟踪40:基金配长缩量
Tebon Securities· 2025-04-07 03:15
1. Report Industry Investment Rating No information provided in the given content. 2. Report's Core View - In the week from March 31 to April 3, after the cross - quarter, the capital interest rate declined, the net financing of large banks' lending increased, the net financing of certificates of deposit increased, and the issuance interest rates of certificates of deposit with various maturities generally decreased. In the cash bond trading, the main buyers were funds, but the scale of their net purchases decreased, mainly concentrated in 7 - 10Y interest - rate bonds and credit bonds within 1Y [3]. 3. Summary by Relevant Catalogs 3.1 Monetary and Capital Market - **Open - market operations**: There were 1186.8 billion yuan of reverse repurchases due this week. The central bank injected 684.9 billion yuan of reverse repurchases from Monday to Thursday, with a net liquidity injection of - 501.9 billion yuan for the whole week [5][10]. - **Funding rates**: As of April 3, R001, R007, DR001, and DR007 were 1.66%, 1.74%, 1.62%, and 1.7% respectively, with changes of - 12.02BP, - 51.42BP, - 9.58BP, and - 35.28BP compared to March 28, and were at the 26%, 13%, 26%, and 9% historical quantiles respectively [5][13]. - **Net financing of main institutions**: The net financing of major lending institutions (large commercial banks/policy banks and joint - stock commercial banks) was 347 billion yuan for the whole week (March 31 - April 3), an increase of 1058.7 billion yuan compared with the previous week. The net financing of fund companies and securities companies was - 5.58 billion yuan and 3.02 billion yuan respectively, with a decrease of 27.74 billion yuan and 3.03 billion yuan compared with the previous week [5][16]. - **Pledged repurchase volume and overnight repurchase ratio**: The average daily trading volume of pledged repurchase was 60.8 trillion yuan, a 4% decrease from the previous week's average daily value. The average daily proportion of overnight repurchase was 86.4%, an increase of 4.53 percentage points from the previous week's average daily value, and was at the 60.4% quantile as of April 3 [5][23]. - **Leverage ratios of institutions**: As of April 3, the leverage ratios of banks, securities, insurance, and broad - based funds were 103.0%, 198.2%, 129.1%, and 105.4% respectively, with changes of 0.09BP, 1.51BP, - 3.17BP, and - 0.07BP compared to March 28, and were at the 9%, 17%, 77%, and 37% historical quantiles respectively [5][24]. 3.2 Certificates of Deposit and Bills - **Issuance and net financing of certificates of deposit**: The total issuance of certificates of deposit was 272.01 billion yuan, a decrease of 557.69 billion yuan from the previous week. The total amount due was 101.54 billion yuan, a decrease of 718.38 billion yuan from the previous week. The net financing was 170.47 billion yuan, an increase of 160.69 billion yuan from the previous week [5][29]. - **Issuance by bank type**: Joint - stock commercial banks had the highest issuance scale. The issuance scales of state - owned banks, joint - stock commercial banks, city commercial banks, and rural commercial banks were 54.76 billion yuan, 107.63 billion yuan, 81.88 billion yuan, and 18.05 billion yuan respectively, with changes of - 321.10 billion yuan, - 72.82 billion yuan, - 148.51 billion yuan, and - 18.28 billion yuan compared to the previous week [29]. - **Issuance by maturity type**: The 1Y certificates of deposit had the highest issuance scale. The issuance scales of 1M, 3M, 6M, 9M, and 1Y certificates of deposit were 18.81 billion yuan, 82.13 billion yuan, 2.95 billion yuan, 19.72 billion yuan, and 148.4 billion yuan respectively, with changes of - 62.91 billion yuan, - 229.59 billion yuan, - 108.97 billion yuan, - 53.27 billion yuan, and - 102.95 billion yuan compared to the previous week [30]. - **Interest rates of certificates of deposit**: The issuance interest rates of certificates of deposit of all banks and all maturities decreased. As of April 3, the one - year issuance interest rates of joint - stock commercial banks, state - owned banks, city commercial banks, and rural commercial banks decreased by - 2.18BP, - 3BP, - 7.36BP, and - 5.07BP respectively compared to March 28, and were at the 5%, 7%, 2%, and 2% historical quantiles. The issuance interest rates of 1M, 3M, and 6M certificates of deposit decreased by - 15.38BP, - 3.19BP, and - 2.23BP respectively compared to March 28, and were at the 12%, 8%, and 4% historical quantiles [40]. - **Bill interest rates**: As of April 3, the 3M direct - discount rate, 3M transfer - discount rate, 6M direct - discount rate, and 6M transfer - discount rate of state - owned and joint - stock banks were 1.25%, 1.09%, 1.14%, and 1.12% respectively, with changes of - 58BP, - 66BP, - 25BP, and - 21BP compared to March 28 [5][46]. 3.3 Institutional Behavior Tracking - **Main buyers and sellers of cash bonds**: The main buyers of cash bonds this week were funds, with a net purchase of 125.5 billion yuan, a decrease from the previous week. The main sellers were joint - stock commercial banks, with a net sale of 184.4 billion yuan, also a decrease from the previous week [5][48]. - **Net purchases of different institutions**: - **Funds**: Net - bought 125.5 billion yuan of cash bonds, including an increase of 70.7 billion yuan in interest - rate bonds, 37.1 billion yuan in credit bonds, 33.5 billion yuan in other bonds (including Tier 2 capital bonds and perpetual bonds), and a decrease of 15.7 billion yuan in certificates of deposit. In terms of maturity, interest - rate bonds were mainly concentrated in the 7 - 10Y range, and credit bonds were mainly within 1Y [48]. - **Wealth management products**: Net - bought 50.2 billion yuan of cash bonds, including an increase of 12.3 billion yuan in interest - rate bonds, 8.7 billion yuan in credit bonds, 6.3 billion yuan in other bonds, and an increase of 23 billion yuan in certificates of deposit. Interest - rate and credit bonds were mainly within 1Y [49]. - **Rural financial institutions**: Net - bought 39.7 billion yuan of cash bonds, including a decrease of 24.8 billion yuan in interest - rate bonds, an increase of 200 million yuan in credit bonds, an increase of 2.3 billion yuan in other bonds, and an increase of 61.9 billion yuan in certificates of deposit. Interest - rate bonds were mainly reduced in the 7 - 10Y range, and credit bonds were mainly increased in the 1 - 3Y range [49]. - **Insurance companies**: Net - bought 30.2 billion yuan of cash bonds, including an increase of 23 billion yuan in interest - rate bonds, 1.6 billion yuan in credit bonds, a decrease of 6.3 billion yuan in other bonds, and an increase of 11.8 billion yuan in certificates of deposit. Interest - rate bonds were mainly concentrated in the 15 - 20Y range, and credit bonds were mainly in the 3 - 5Y range [49].
海外市场周报:应对“对等关税”冲击波
Tebon Securities· 2025-04-06 13:30
薛威 资格编号:S0120523080002 邮箱:xuewei@tebon.com.cn 谭诗吟 资格编号:S0120523070007 邮箱:tansy@tebon.com.cn 证券研究报告 | 海外市场周报 2025 年 4 月 6 日 [Table_Main] 海外市场周报 证券分析师 应对"对等关税"冲击波 [Table_Summary] 投资要点: 请务必阅读正文之后的信息披露和法律声明 上周全球股市集体回调。沪深 300 和中国台湾加权指数跌幅较小。美股三大指数 大幅回调,道指、标普 500 和纳指涨跌幅分别为-7.9%、-9.1%和-10.0%,在大非 农数据超预期的背景下,美股并未止跌,并在鲍威尔稍后的偏鹰发言后加速下行; 欧洲市场三大主要指数集体回调;亚太地区除日本和越南外回调幅度相对较小。 各国应对"对等关税"的差异为何如此之大?周四凌晨的"对等关税"发布后,各 国应对方式分化显著。中国率先对等反制,欧盟表态将进行反制,拒绝单方面让步; 部分国家正争取谈判空间;日、韩等则以妥协为主;大多数中小型经济体则不明确 表态。各国应对方式分化显著的原因有二,一是对内需的信心有差别,市场庞大的 中 ...
医药行业周报:中国创新药逐步进入收获期,关注技术革新与BD潜力-2025-04-06
Tebon Securities· 2025-04-06 13:08
Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [2] Core Insights - The Chinese innovative drug sector is entering a harvest period, with a focus on technological innovation and business development (BD) potential [5] - Companies such as Sangfor Biopharma, Kexing Pharmaceutical, and Yifang Biotech are highlighted for their strong growth prospects and innovative pipelines [4][5] Summary by Sections 1. Chinese Innovative Drugs Entering Harvest Period - **Sangfor Biopharma**: Core products are showing steady growth, and the innovative pipeline is gradually yielding results. The PD-1/VEGF dual antibody AK112 has become the first drug to outperform K drug in head-to-head Phase III clinical trials, enhancing the development enthusiasm for PD(L)-1/VEGF dual antibodies. The company has three ongoing clinical trials demonstrating excellent efficacy and BD potential [7][8] - **Kexing Pharmaceutical**: The CAR-T therapy shows significant potential, with its first product, CT053, approved for treating multiple myeloma in February 2024. Another product, CT041, is a potential first-in-class CAR-T for Claudin18.2, with a Phase II trial for gastric cancer completed. The company is well-positioned in the universal CAR-T technology space [11][12] - **Yifang Biotech**: The drug D-2570 shows promising data for treating psoriasis, with clinical results indicating significant efficacy compared to placebo. The drug is in Phase II trials and ranks third among domestic products, with a large patient population and a competitive landscape [14][15] 2. Weekly Market Review and Hotspot Tracking (March 31 - April 3, 2025) - The pharmaceutical and biotechnology sector index rose by 1.2%, outperforming the CSI 300 index by 2.57%. Year-to-date, the sector index has increased by 4.77%, also outperforming the CSI 300 index by 6.64 [16][18] - The top five performing stocks during this period included Duorui Pharmaceutical (up 56.32%), Weisi Medical (up 31.80%), and Hasanlian (up 31.15%) [29][32] 3. Overall Investment Strategy and Allocation Thoughts - The development of AI is driving the widespread adoption of AI in healthcare, with many medical companies exploring AI applications. Companies with extensive patient data and those with health insurance data are expected to have significant application potential. The report suggests focusing on innovative drugs and companies with a turning point in fundamentals [4][5]
海外市场周报:应对“对等关税”冲击波-2025-04-06
Tebon Securities· 2025-04-06 12:13
证券研究报告 | 海外市场周报 2025 年 4 月 6 日 [Table_Main] 海外市场周报 证券分析师 薛威 资格编号:S0120523080002 邮箱:xuewei@tebon.com.cn 谭诗吟 资格编号:S0120523070007 邮箱:tansy@tebon.com.cn 应对"对等关税"冲击波 [Table_Summary] 投资要点: 请务必阅读正文之后的信息披露和法律声明 上周全球股市集体回调。沪深 300 和中国台湾加权指数跌幅较小。美股三大指数 大幅回调,道指、标普 500 和纳指涨跌幅分别为-7.9%、-9.1%和-10.0%,在大非 农数据超预期的背景下,美股并未止跌,并在鲍威尔稍后的偏鹰发言后加速下行; 欧洲市场三大主要指数集体回调;亚太地区除日本和越南外回调幅度相对较小。 各国应对"对等关税"的差异为何如此之大?周四凌晨的"对等关税"发布后,各 国应对方式分化显著。中国率先对等反制,欧盟表态将进行反制,拒绝单方面让步; 部分国家正争取谈判空间;日、韩等则以妥协为主;大多数中小型经济体则不明确 表态。各国应对方式分化显著的原因有二,一是对内需的信心有差别,市场庞大的 中 ...
“国产化”,风云再起
Tebon Securities· 2025-04-06 07:40
[Table_Main] 证券研究报告 | 行业周报 计算机 优于大市(维持) 证券分析师 陈涵泊 资格编号:S0120524040004 邮箱:chenhb3@tebon.com.cn 王思 邮箱:wangsi@tebon.com.cn 市场表现 -27% -13% 0% 13% 27% 40% 54% 2024-04 2024-08 2024-12 计算机 沪深300 资料来源:德邦研究所,聚源数据 研究助理 相关研究 1.《IDC:供需格局改善,AIDC 开启 行业新周期》,2025.3.31 2.《中科星图:"小米造车式创新"效 果显现, AI+低空应用场景加速落 地》,2025.3.30 3.《GPT-4o 原生图像告别"AI 味", 进阶为生产力工具》,2025.3.29 4.《政府报告首提深海科技,万亿市 场有望打开》,2025.3.22 5.《中科星图:迈向 AI Saas+数据分 析未来》,2025.3.5 计算机 2025 年 04 月 05 日 "国产化",风云再起 [Table_Summary] 投资要点: 请务必阅读正文之后的信息披露和法律声明 关税对抗加剧,国产化内循环修炼内功重要 ...
煤炭周报:成本支撑显现,煤价止跌企稳
Tebon Securities· 2025-04-06 07:35
煤炭 优于大市(维持) 谢佶圆 邮箱:xiejy@tebon.com.cn 市场表现 -29% -22% -15% -7% 0% 7% 15% 22% 29% 2024-04 2024-08 2024-12 煤炭开采 沪深300 证券分析师 翟堃 资格编号:s0120523050002 邮箱:zhaikun@tebon.com.cn 研究助理 资料来源:聚源数据、德邦研究所 相关研究 1.《中国旭阳集团(1907.HK): 传统业务显韧性,新兴领域迎发 展》,2025.4.3 2.《兖矿能源(600188.SH):成 本管控优异,成长空间广阔》, 2025.3.30 3.《煤炭周报:红利价值不改,把 握低位布局》,2025.3.30 4.《淮北矿业(600985.SH):成本优 化对冲量价影响,多业务布局持续 成长》,2025.3.29 5.《煤炭周报:预期底部夯实,静 待需求复苏》,2025.3.23 煤炭开采 2025 年 04 月 06 日 煤炭周报:成本支撑显现,煤价 止跌企稳 [Table_Summary] 投资要点: 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 终端需求持续 ...
卫星互联网手机宽带直连,天地融合通信将加速
Tebon Securities· 2025-04-06 07:30
[Table_Main] 证券研究报告 | 行业周报 通信 优于大市(维持) 证券分析师 李宏涛 资格编号:S0120524070003 邮箱:liht@tebon.com.cn 研究助理 市场表现 -20% -10% 0% 10% 20% 29% 39% 49% 2024-04 2024-08 2024-12 通信 沪深300 资料来源:德邦研究所,聚源数据 相关研究 1.《运营商投资向算力倾斜,AIDC 具 有持续性》,2025.3.29 2.《中国移动(600941.SH):HBN 拉 动业务增长,算力转型走深走实》, 2025.3.28 1. 投资策略 请务必阅读正文之后的信息披露和法律声明 1.1 我国手机直连卫星实验开始,天地融合通信闭环加速。4 月 1 日,我国成功将 卫星互联网技术试验卫星发射升空,卫星顺利进入预定轨道,发射任务获得圆满成 功。该卫星主要用于开展手机宽带直连卫星、天地网络融合等技术试验验证。我们 认为,如果此次实验成功,或意味着手机等终端将可以直接通过卫星开展业务。这 可能将从需求端拉动卫星互联网建设加速。1、卫星终端需求已被市场初步证实。 2 月 26 日,中国电信发布"20 ...
煤炭周报:成本支撑显现,煤价止跌企稳-2025-04-06
Tebon Securities· 2025-04-06 05:15
煤炭 优于大市(维持) 证券分析师 翟堃 资格编号:s0120523050002 邮箱:zhaikun@tebon.com.cn 研究助理 谢佶圆 邮箱:xiejy@tebon.com.cn 市场表现 -29% -22% -15% -7% 0% 7% 15% 22% 29% 2024-04 2024-08 2024-12 煤炭开采 沪深300 资料来源:聚源数据、德邦研究所 相关研究 1.《中国旭阳集团(1907.HK): 传统业务显韧性,新兴领域迎发 展》,2025.4.3 2.《兖矿能源(600188.SH):成 本管控优异,成长空间广阔》, 2025.3.30 3.《煤炭周报:红利价值不改,把 握低位布局》,2025.3.30 4.《淮北矿业(600985.SH):成本优 化对冲量价影响,多业务布局持续 成长》,2025.3.29 5.《煤炭周报:预期底部夯实,静 待需求复苏》,2025.3.23 煤炭开采 2025 年 04 月 06 日 煤炭周报:成本支撑显现,煤价 止跌企稳 [Table_Summary] 投资要点: 请务必阅读正文之后的信息披露和法律声明 证券研究报告 | 行业周报 终端需求持续 ...